Clinical Trial: Phase III Clinical Trial of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome)

U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07610434) titled 'Phase III Clinical Trial of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome)' on May 17.

Brief Summary: This trial is a randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase III clinical trial. Its purpose is to evaluate the efficacy and safety of Changji'an Capsules in subjects with diarrhea-predominant irritable bowel syndrome (liver-qi invading spleen syndrome) after 8 weeks of treatment.

Study Start Date: May 31

Study Type: INTERVENTIONAL

Condition: IBS, Diarrhea Predominant

Intervention: DRUG: Chang Ji'an capsule

The pr...